These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 16551338)

  • 1. Effect of glucagon-like peptide-1 on the beta cell response to glucose-dependent insulinotropic polypeptide in elderly patients with diabetes mellitus.
    Meneilly GS; Elahi D
    J Am Geriatr Soc; 2006 Mar; 54(3):554-5. PubMed ID: 16551338
    [No Abstract]   [Full Text] [Related]  

  • 2. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of cyclic nucleotides and cyclic nucleotide phosphodiesterases in pancreatic islet beta-cells and intestinal L-cells as targets for treating diabetes mellitus.
    Furman B; Pyne N
    Curr Opin Investig Drugs; 2006 Oct; 7(10):898-905. PubMed ID: 17086934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
    Ranganath LR
    J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
    Mest HJ
    Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.
    Müssig K; Oncü A; Lindauer P; Heininger A; Aebert H; Unertl K; Ziemer G; Häring HU; Holst JJ; Gallwitz B
    Am J Cardiol; 2008 Sep; 102(5):646-7. PubMed ID: 18721530
    [No Abstract]   [Full Text] [Related]  

  • 10. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
    Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
    Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
    Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
    Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
    Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
    Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathophysiologic role of incretins.
    Freeman JS
    J Am Osteopath Assoc; 2007 May; 107 Suppl():S6-9. PubMed ID: 17724014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
    Gribble FM
    Diabet Med; 2008 Aug; 25(8):889-94. PubMed ID: 18959599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic approaches to preserve islet mass in type 2 diabetes.
    Baggio LL; Drucker DJ
    Annu Rev Med; 2006; 57():265-81. PubMed ID: 16409149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats.
    Pacheco D; de Luis DA; Romero A; González Sagrado M; Conde R; Izaola O; Aller R; Delgado A
    Am J Surg; 2007 Aug; 194(2):221-4. PubMed ID: 17618808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT.
    He YL; Wang Y; Bullock JM; Deacon CF; Holst JJ; Dunning BE; Ligueros-Saylan M; Foley JE
    J Clin Pharmacol; 2007 May; 47(5):633-41. PubMed ID: 17442688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
    Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
    Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.